72 related articles for article (PubMed ID: 26456124)
1. Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.
Varmeh S; Vanden Borre P; Gunda V; Brauner E; Holm T; Wang Y; Sadreyev RI; Parangi S
Surgery; 2016 Jan; 159(1):152-62. PubMed ID: 26456124
[TBL] [Abstract][Full Text] [Related]
2. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
4. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
[TBL] [Abstract][Full Text] [Related]
5. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
[TBL] [Abstract][Full Text] [Related]
6. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S
Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332
[TBL] [Abstract][Full Text] [Related]
7. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
8. The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors.
Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Muzza M; Capelli V; Latrofa F; Persani L; Chiovato L; Rotondi M
Sci Rep; 2019 Mar; 9(1):4390. PubMed ID: 30867499
[TBL] [Abstract][Full Text] [Related]
9. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
[TBL] [Abstract][Full Text] [Related]
10. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
Gunda V; Cogdill AP; Bernasconi MJ; Wargo JA; Parangi S
Surgery; 2013 Dec; 154(6):1456-62; discussion 1462. PubMed ID: 24238058
[TBL] [Abstract][Full Text] [Related]
11. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.
Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586
[TBL] [Abstract][Full Text] [Related]
13. Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.
Limberg J; Egan CE; Gray KD; Singh M; Loewenstein Z; Yang Y; Riascos MC; Al Asadi H; Safe P; El Eshaky S; Liang H; Ullmann TM; Wang W; Li W; Zhang T; Xiang J; Stefanova D; Jin MM; Zarnegar R; Fahey TJ; Min IM
Mol Cancer Res; 2023 May; 21(5):397-410. PubMed ID: 36790391
[TBL] [Abstract][Full Text] [Related]
14. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.
Capaldo BJ; Roller D; Axelrod MJ; Koeppel AF; Petricoin EF; Slingluff CL; Weber MJ; Mackey AJ; Gioeli D; Bekiranov S
PLoS One; 2015; 10(9):e0138210. PubMed ID: 26405815
[TBL] [Abstract][Full Text] [Related]
15. Discussion.
Surgery; 2016 Jan; 159(1):162. PubMed ID: 26456132
[No Abstract] [Full Text] [Related]
16. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
Nehs MA; Nucera C; Nagarkatti SS; Sadow PM; Morales-Garcia D; Hodin RA; Parangi S
Endocrinology; 2012 Feb; 153(2):985-94. PubMed ID: 22202162
[TBL] [Abstract][Full Text] [Related]
17. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant thyroid cancer cells in 2D and 3D culture.
Ingeson-Carlsson C; Martinez-Monleon A; Nilsson M
Exp Cell Res; 2015 Nov; 338(2):127-35. PubMed ID: 26384551
[TBL] [Abstract][Full Text] [Related]
19. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
Hanly EK; Tuli NY; Bednarczyk RB; Suriano R; Geliebter J; Moscatello AL; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2016 Feb; 7(8):8676-87. PubMed ID: 26735176
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Exp Cell Res; 2015 Dec; 339(2):342-50. PubMed ID: 26384552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
